Veracyte Q2 2026: A Margin-Driven Run With Medicare Momentum and New Tests

Veracyte, Inc. (Nasdaq: VCYT) delivered a second-quarter 2026 in which headline comfort came from growth in testing revenue and a cash-rich balance sheet. The press release lays out EPS-style profitability signals via GAAP net income and adjusted EBITDA, even as the company refrains from a formal revenue forecast for the near term. In public markets chatter, analysts will likely watch for EPS consensus alignment and any earnings surprise versus expectations, given the strong operating cash flow and expanding margins.

Key numbers at a glance

Total revenue: $150.3 million, up 15% year over year.
Testing revenue: $145.7 million, up 19% YoY.
Product revenue: $3.9 million, up 7% YoY.
Biopharmaceutical and other revenue: $0.8 million, down from $4.3 million in prior-year quarter due to restructuring and liquidation of Veracyte SAS.
GAAP net income: $25.5 million, or 17.0% of revenue.
Adjusted EBITDA: $44.0 million, or 29.2% of revenue.
Total volume: 50,967 tests (testing volume: 48,389 tests).
Decipher growth: approximately $91.9 million in testing revenue; Afirma growth to about $51.2 million.
Liquidity: $485.2 million of cash, cash equivalents, and short-term investments as of 6/30/2026.

The above figures reflect a quarter where the core testing portfolio continues to drive growth, while the company’s financial discipline yields margin improvements—GAAP gross margin at 72% (non-GAAP 75%), with operating expenses of $85.6 million guiding the bottom-line path toward profitability.

Strategic moves shaping the quarter

The press release highlights two new products that are more than cosmetic upgrades: Prosigna LDT and TrueMRD for muscle-invasive bladder cancer (MIBC). Veracyte also announced Medicare coverage for the TrueMRD Monitoring Test, marking a milestone for a whole-genome sequencing–based platform and signaling a potential expansion of addressable reimbursement.

Beyond products and payer momentum, Veracyte emphasized expanding the clinical evidence base, including predictive data from the OPTIMA trial and the ENZAMET trial, with Decipher and Afirma contributions featured across nearly 60 abstracts and presentations in the quarter. The company frames these efforts as accelerants to the core growth engine rather than a temporary tailwind.

Margins, cash flow, and the balance sheet

Veracyte reports a solid margin story: total gross margin of 72% in Q2 2026, up from 69% a year earlier, with non-GAAP gross margin at 75%. This margin expansion accompanies a robust quarterly cash flow, $45.8 million in cash from operations, underpinning a liquidity cushion of $485.2 million at quarter-end.

The GAAP net income of $25.5 million, paired with a 17.0% revenue margin, supports the narrative that the business is generating meaningful profitability within its test-heavy portfolio. Adjusted EBITDA of $44.0 million adds a peer-friendly proxy for operating cash profitability, which downstream investors will juxtapose against reported net income for an earnings-quality read.

Outlook and implications for the sector

The quarter’s results showcase a company that is not merely riding a wave of testing volume but actively expanding its product and evidence ecosystem. The Medicare coverage for TrueMRD and the Prosigna LDT launch reflect a payer-and-product dynamic that could pressure peers to accelerate their own evidence generation and payer engagement. In a sector where EPS and EPS consensus matter, Veracyte’s margin improvement and strong cash generation raise the bar for profitability in molecular diagnostics, even as forward visibility remains muted by the absence of a formal revenue forecast in this release.

For sector peers, the takeaway is twofold. First, growth can be concentrated not just in volumes but in value-added tests with payer validation. Second, the strategic mix—expanding the test portfolio while securing reimbursement—appears to be a durable path to sustain revenue forecast realism, even if the company has not issued updated guidance. Investors and analysts will likely translate these signals into forward-looking EPS estimates, watching closely for any uplift in earnings surprise relative to consensus as additional quarters unfold.

Notes and disclosure context

Veracyte reiterates that a reconciliation of GAAP to non-GAAP financial measures is provided in the press release. This is the kind of disclosure that makes the EPS discussion more tractable for analysts who must separate one-time or restructuring effects from core operating performance.

The company will host a conference call and webcast at 4:30 p.m. ET to discuss the quarter, which should provide further color on trajectory, product uptake, and the pace of Medicare and other payer approvals—areas likely to influence the stock’s sensitivity around the next earnings release.

Conclusion

Veracyte’s Q2 2026 narrative combines revenue expansion from its testing portfolio with strategic product launches and payer validation that collectively hint at durable growth in a competitive diagnostics space. While the absence of a stated revenue forecast leaves room for analysts to refine their EPS consensus assumptions, the quality of the cash flow, margins, and strategic investments in evidence generation provide a framework for modestly constructive sentiment among peers. In a sector where every test is a potential revenue line and every payer decision can tilt a quadrant of the market, Veracyte’s quarterly results read as a steady, data-driven calibration rather than a one-off sprint.